← Back to all trials
Recruiting
NCT07808697
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
Conditions: SARS-CoV-2
Sex: All
Ages: 6 Months – 11 Years
Healthy volunteers: Yes
Phase: PHASE2
Enrollment: 300
Sponsor: ModernaTX, Inc.
Location: Orange County Research Center Ontario California
Summary
This study will evaluate 2 dose levels of mRNA-1283 in participants ≥6 months to \
Eligibility Criteria
Key Inclusion Criteria:
* Participant is male or female, between ≥2 years to \
Source: ClinicalTrials.gov (NCT07808697). StuddyBuddy aggregates publicly available trial information.
